Sunny Uberoi joins Aditxt Therapeutics to raise the company’s profile in advance of initiating its first-in-human clinical trials and support the rapid scaling of AditxtScore, a commercial technology platform designed to provide a personalized, comprehensive profile of the immune system.
Sunny Uberoi will be responsible for leading global corporate communications, investor relations, and government affairs.
“Aditxt is a strong purpose-led brand with an emerging community of stakeholders around the world. To achieve our commitments to growing our brand authentically, we need the right executives to support our mission and business model. Sunny brings a unique combination of senior leadership experience in healthtech, financial services and biopharmaceuticals, and his guidance will be critical to the next phase of growth for our company,” said Amro Albanna, co-founder and CEO of Aditxt. ”
Most recently, Uberoi served as the Vice President of Corporate Affairs for Global Drug Development, Research and Early Development, and Global Product Supply at Bristol Myers Squibb. Uberoi also led communications for S&P Global Market Intelligence, including the asset divesture of J.D. Power. Before that, he was the Head of Corporate Stakeholder Engagement at Deloitte as well as the Head of Global Communications for Consumer Health at Pfizer.
Uberoi earned his bachelor’s degree in Economics from The Manchester Metropolitan University and a Master’s degree in Marketing from The University of Manchester.